Herbalife (NYSE:HLF – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.
Several other research firms also recently commented on HLF. Mizuho boosted their target price on shares of Herbalife from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday. B. Riley lowered their price objective on Herbalife from $17.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday. Citigroup dropped their target price on shares of Herbalife from $16.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Finally, DA Davidson dropped their price target on Herbalife from $13.00 to $7.50 and set a “neutral” rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.42.
Get Our Latest Stock Analysis on Herbalife
Herbalife Stock Performance
Herbalife (NYSE:HLF – Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.19 by $0.38. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Herbalife had a negative return on equity of 18.66% and a net margin of 1.73%. Analysts expect that Herbalife will post 1.34 EPS for the current year.
Insiders Place Their Bets
In other news, Director Juan Miguel Mendoza bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was acquired at an average price of $8.72 per share, for a total transaction of $87,200.00. Following the transaction, the director now directly owns 110,000 shares of the company’s stock, valued at $959,200. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.94% of the company’s stock.
Hedge Funds Weigh In On Herbalife
Institutional investors and hedge funds have recently bought and sold shares of the business. Harbor Capital Advisors Inc. lifted its position in shares of Herbalife by 139.4% during the third quarter. Harbor Capital Advisors Inc. now owns 38,020 shares of the company’s stock worth $273,000 after purchasing an additional 22,138 shares in the last quarter. Iridian Asset Management LLC CT lifted its holdings in Herbalife by 43.7% during the 3rd quarter. Iridian Asset Management LLC CT now owns 2,228,193 shares of the company’s stock worth $16,021,000 after buying an additional 677,739 shares in the last quarter. Diversify Wealth Management LLC boosted its position in Herbalife by 271.4% in the 3rd quarter. Diversify Wealth Management LLC now owns 159,499 shares of the company’s stock valued at $1,113,000 after buying an additional 116,548 shares during the last quarter. Carolina Wealth Advisors LLC bought a new stake in shares of Herbalife during the third quarter worth $78,000. Finally, Avaii Wealth Management LLC boosted its holdings in Herbalife by 12.4% in the third quarter. Avaii Wealth Management LLC now owns 39,264 shares of the company’s stock valued at $282,000 after acquiring an additional 4,347 shares during the last quarter.
Herbalife Company Profile
Herbalife Ltd. provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers products in the areas of weight management; targeted nutrition; energy, sports, and fitness; outer nutrition; and literature and promotional items.
Featured Stories
- Five stocks we like better than Herbalife
- Basic Materials Stocks Investing
- Intel: Is Now the Time to Be Brave?
- Stock Sentiment Analysis: How it Works
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Plot Fibonacci Price Inflection Levels
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Herbalife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Herbalife and related companies with MarketBeat.com's FREE daily email newsletter.